Furosemide
Furoscix, Furosemide, Lasix (furosemide) is a small molecule pharmaceutical. Furosemide was first approved as Furosemide on 1982-01-01. It is used to treat ascites, chronic kidney failure, edema, heart failure, and hypertension amongst others in the USA. The pharmaceutical is active against solute carrier family 12 member 1. In addition, it is known to target solute carrier family 12 member 2 and G-protein coupled receptor 35.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Furoscix, Furosemide, Lasix (discontinued: Furosemide, Lasix)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Furosemide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| FUROSEMIDE | Epic Pharma | N-018569 RX | 1982-01-01 | 3 products |
| FUROSEMIDE | Fresenius Kabi | N-018902 RX | 1984-05-22 | 1 products |
| FUROSEMIDE | Hikma Pharmaceuticals | N-018267 RX | 1982-01-01 | 1 products |
| FUROSEMIDE | Hikma Pharmaceuticals | N-018823 RX | 1983-11-10 | 2 products |
| FUROSEMIDE | Hospira | N-018667 RX | 1982-05-28 | 1 products |
| FUROSCIX | scPharmaceuticals | N-209988 RX | 2022-10-07 | 1 products, RLD, RS |
| LASIX | Validus Pharmaceuticals | N-016273 RX | 1982-01-01 | 3 products, RLD, RS |
Show 18 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 14-panel toxicology medicated collection system | ANDA | 2022-03-29 |
| diascreen 12-panel medicated collection system | ANDA | 2022-02-25 |
| furoscix | New Drug Application | 2025-08-12 |
| furosemide | ANDA | 2025-10-02 |
| lasix | New Drug Application | 2025-09-30 |
| rx-specimen collection kit | ANDA | 2018-02-22 |
| toxicology medicated collection system | ANDA | 2022-04-05 |
| toxycology medicated collection system | ANDA | 2022-02-25 |
| udsx medicated system | unapproved drug other | 2025-06-12 |
| udsxmp medicated system | unapproved drug other | 2025-06-12 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
ATC Codes
C: Cardiovascular system drugs
— C03: Diuretics
— C03C: High-ceiling diuretics
— C03CA: Sulfonamides, high-ceiling diuretics, plain
— C03CA01: Furosemide
— C03CB: Sulfonamides and potassium in combination, high-ceiling diruetics, excluding thiazides
— C03CB01: Furosemide and potassium
— C03E: Diuretics and potassium-sparing agents in combination
— C03EB: High-ceiling diuretics and potassium-sparing agents
— C03EB01: Furosemide and potassium-sparing agents
HCPCS
Code | Description |
|---|---|
| J1940 | Injection, furosemide, up to 20 mg |
Clinical
Clinical Trials
401 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | 15 | 30 | 34 | 38 | 40 | 144 |
| Acute kidney injury | D058186 | — | N17 | 1 | 3 | 3 | 5 | 15 | 25 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 3 | 2 | 7 | 8 | 20 |
| Renal insufficiency | D051437 | — | N19 | 3 | 3 | 3 | 4 | 7 | 20 |
| Chronic renal insufficiency | D051436 | — | N18 | 1 | 2 | 2 | 7 | 3 | 15 |
| Critical illness | D016638 | — | — | — | 3 | 4 | 1 | 8 | 14 |
| Edema | D004487 | — | R60.9 | 1 | — | 4 | 6 | 1 | 12 |
| Iron overload | D019190 | — | — | 1 | 1 | 2 | 5 | 3 | 12 |
| Dyspnea | D004417 | — | R06.0 | 4 | 3 | 5 | 1 | 1 | 11 |
| Water intoxication | D014869 | — | — | 1 | 1 | 3 | 4 | 2 | 11 |
Show 38 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardio-renal syndrome | D059347 | — | — | — | 2 | 2 | — | 3 | 7 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | 1 | — | 3 | 4 |
| Respiratory insufficiency | D012131 | — | J96.9 | — | 1 | 2 | — | 2 | 4 |
| Bronchiolitis | D001988 | — | — | 1 | 1 | 1 | — | — | 3 |
| Inflammation | D007249 | MP_0001845 | — | 1 | 1 | 1 | — | 1 | 3 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | — | 2 | — | 1 | 3 |
| Cardiac surgical procedures | D006348 | — | — | — | — | 1 | — | 2 | 3 |
| Kidney calculi | D007669 | EFO_0004253 | N20 | — | — | 1 | — | 2 | 3 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | 1 | — | 1 | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | 1 | — | — | 2 |
Show 35 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 19 | 1 | — | — | 3 | 22 |
| Wounds and injuries | D014947 | — | T14.8 | — | 1 | — | — | 7 | 8 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 2 | — | — | 3 | 5 |
| Neoplasms | D009369 | — | C80 | 3 | 2 | — | — | — | 4 |
| Acute lung injury | D055371 | EFO_0004610 | — | — | 1 | — | — | 3 | 4 |
| Leukemia | D007938 | — | C95 | 2 | 1 | — | — | 1 | 3 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 1 | — | — | — | 2 |
| Myelodysplastic syndromes | D009190 | — | D46 | 2 | 1 | — | — | — | 2 |
| Multiple myeloma | D009101 | — | C90.0 | 2 | 1 | — | — | — | 2 |
| Lymphoma | D008223 | — | C85.9 | 2 | 1 | — | — | — | 2 |
Show 19 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dehydration | D003681 | — | E86.0 | 1 | — | — | — | 4 | 5 |
| Pulmonary arterial hypertension | D000081029 | — | — | 1 | — | — | — | 2 | 3 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | 1 | — | — | — | 1 | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | 1 | 2 |
| Drug interactions | D004347 | — | — | 2 | — | — | — | — | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | — | — | — | — | 1 |
| Food-drug interactions | D018565 | — | — | 1 | — | — | — | — | 1 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | — | — | — | — | 1 |
| Peritoneal neoplasms | D010534 | — | — | 1 | — | — | — | — | 1 |
| Crush injuries | D000071576 | — | T14.8 | 1 | — | — | — | — | 1 |
Show 14 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Newborn respiratory distress syndrome | D012127 | — | P22 | — | — | — | — | 3 | 3 |
| Septic shock | D012772 | — | A48.3 | — | — | — | — | 3 | 3 |
| Hyperemia | D006940 | EFO_0003822 | H34.82 | — | — | — | — | 3 | 3 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 2 | 2 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 2 | 2 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | — | 2 | 2 |
| Fluid therapy | D005440 | — | — | — | — | — | — | 2 | 2 |
| Postoperative complications | D011183 | — | — | — | — | — | — | 2 | 2 |
| Shock | D012769 | — | R57.1 | — | — | — | — | 2 | 2 |
| Diuresis | D004231 | — | — | — | — | — | — | 2 | 2 |
Show 77 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Furosemide |
| INN | furosemide |
| Description | Furosemide is a chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure. It has a role as a xenobiotic, an environmental contaminant and a loop diuretic. It is a sulfonamide, a chlorobenzoic acid and a member of furans. |
| Classification | Small molecule |
| Drug class | diuretics (furosemide type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl |
Identifiers
| PDB | — |
| CAS-ID | 54-31-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL35 |
| ChEBI ID | 47426 |
| PubChem CID | 3440 |
| DrugBank | DB00695 |
| UNII ID | 7LXU5N7ZO5 (ChemIDplus, GSRS) |
Target
Agency Approved
SLC12A1
SLC12A1
Organism
Homo sapiens
Gene name
SLC12A1
Gene synonyms
NKCC2
NCBI Gene ID
Protein name
solute carrier family 12 member 1
Protein synonyms
bumetanide-sensitive cotransporter type 1, Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2, Kidney-specific Na-K-Cl symporter, Na-K-2Cl cotransporter, Na-K-2Cl cotransporter 2, solute carrier family 12 (sodium/potassium/chloride transporter), member 1, solute carrier family 12 (sodium/potassium/chloride transporters), member 1
Uniprot ID
Mouse ortholog
Slc12a1 (20495)
solute carrier family 12 member 1 (P55014)
Alternate
CISD1
CISD1
Organism
Homo sapiens
Gene name
CISD1
Gene synonyms
C10orf70, ZCD1
NCBI Gene ID
Protein name
CDGSH iron-sulfur domain-containing protein 1
Protein synonyms
Cysteine transaminase CISD1, MitoNEET, zinc finger CDGSH-type domain 1
Uniprot ID
Mouse ortholog
Cisd1 (52637)
CDGSH iron-sulfur domain-containing protein 1 (Q91WS0)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Furosemide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 40,972 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
70,403 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use